The PROTECT open-label randomised basket trial will assess the effectiveness of hydroxychloroquine (HCQ) as chemoprophylaxis against COVID-19 in multiple vulnerable populations in the United Kingdom.
Inclusion Criteria: * Have no previous confirmed COVID-19 diagnosis * Fall into one of the high risk population groups Exclusion Criteria: * Inability to provide informed consent * Symptomatic for possible COVID-19 at baseline or symptoms highly suggestive of COVID-19 experienced since 1st March 2020 * Hypersensitivity reaction to hydroxychloroquine, chloroquine or 4-aminoquinolines or any formulation excipients * Contraindication to taking hydroxychloroquine as prophylaxis e.g known epilepsy * Already taking chloroquine, hydroxychloroquine or 4-aminoquinolines * History of any retinopathy including diabetic retinopathy requiring laser therapy * Taking medications which are contra-indicated alongside HCQ - Digoxin, Halofantrine, Amiodarone, Moxifloxacin, Cyclosporin, Mefloquine, Praziquantel, Tamoxifen * Known history of prolonged QTc * Type I diabetes or insulin-dependent type II diabetes
No linked publications found in PubMed